Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA & Nathan DM (2002): Diabetes-Prevention PRG. 50, 60–64.ĭe Luca G, Calpona PR, Caponetti A, Macaione V, Di Benedetto A, Cucinotta D & Di Giorgio RM (2001b): Amino acid profile in platelets of diabetic patients. 237, E214–E223.ĭe Luca G, Calpona PR, Caponetti A, Romano G, Di Benedetto A, Cucinotta D & Di Giorgio RM (2001a): Taurine and osmoregulation: platelet taurine content, uptake, and release in type 2 diabetic patients. Diabetes Care 14, 173–194.ĭeFronzo RA, Tobin JD & Andres R (1979): Glucose clamp technique: a method for quantifying insulin secretion and resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Type 2-diabetes og det metaboliske syndrom - diagnostik og behandling 6, 1–36.Ĭherif H, Reusens B, Ahn MT, Hoet JJ & Remacle C (1998): Effects of taurine on the insulin secretion of rat fetal islets from dams fed a low-protein diet. 94, 1714–1721.īeck-Nielsen H, Henriksen JE, Hermansen K, Madsen LD, Olivarius NF, Mandrup-Poulsen TR, Pedersen OB, Richelsen B & Schmidtz OE (2000): Klaringsrapport. 15, 539–553.īeck-Nielsen H & Groop LC (1994): Metabolic and genetic characterization of prediabetic states: sequence of events leading to non-insulin-dependent diabetes mellitus. Provisional report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. 77, 749–754.Īlberti KGMM & Zimmet PZ (1998): Definition, diagnosis and classification of diabetes mellitus and its complications. These findings in persons with an increased risk of T2DM are in contrast to those from animal studies, and do not support the assumption that dietary supplementation with taurine can be used to prevent the development of T2DM.Īnuradha CV & Balakrishnan SD (1999): Taurine attenuates hypertension and improves insulin sensitivity in the fructose-fed rat, an animal model of insulin resistance. There was no significant effect of taurine supplementation on blood lipid levels as well.Ĭonclusion: Daily supplementation with 1.5 g taurine for 8 weeks had no effect on insulin secretion or sensitivity, or on blood lipid levels. Insulin secretion, adjusted for insulin sensitivity, was also unchanged. There was no significant difference after taurine intervention compared to placebo in incremental insulin response (Ins incr.) neither during the IVGTT, nor in insulin-stimulated glucose disposal during the clamp. Results: Mean plasma taurine concentration was 39☗ (s.d.) μmol/l after placebo and 131☖2 μmol/l after taurine intervention ( P<0.0001). An intravenous glucose tolerance test (IVGTT) was used to measure first-phase insulin secretory response, and a euglycemic hyperinsulinemic clamp was used to determine peripheral insulin action. The subjects were overweight first-degree relatives of T2DM patients. Objective: To assess the effect of taurine treatment on insulin secretion and action, and on plasma lipid levels in overweight men with a positive history of T2DM.ĭesign: 20 nondiabetic subjects were included in a double-blinded, randomized, crossover study, receiving a daily supplementation of 1.5 g taurine or placebo for two periods of 8 weeks. Animal studies with taurine supplementation have shown increased insulin secretion and action, suggesting that taurine supplementation may have a potential to prevent T2DM. Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing with an epidemic growth rate.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |